Vevye eye drops are a prescription medication used to treat dry eye disease [1]. The active ingredient in Vevye is cyclosporine ophthalmic emulsion 0.1% [1]. It is manufactured by Novaliq GmbH [1].
How do Vevye eye drops work?
Vevye functions by increasing tear production in patients who have reduced natural tear production due to ocular inflammation associated with dry eye disease [1].
When was Vevye approved by the FDA?
The U.S. Food and Drug Administration (FDA) approved Vevye on May 23, 2023 [1].
What is the recommended dosage for Vevye eye drops?
The recommended dosage for Vevye is one drop instilled into each eye twice daily [1].
What are the potential side effects of Vevye eye drops?
Common side effects reported in clinical studies for Vevye include instillation site pain and conjunctival redness [1]. Other potential side effects include temporary blurred vision upon instillation [1].
What alternatives are available for dry eye disease?
Other treatments for dry eye disease include artificial tears, punctal plugs, and other prescription eye drops like Xiidra and Restasis, which also contain cyclosporine but in different formulations [2].
How does Vevye compare to other cyclosporine eye drops like Restasis?
Vevye is a novel, water-free ophthalmic emulsion that uses EyeSol technology, which is designed to improve drug penetration and retention in the eye [3]. Restasis is an aqueous-based emulsion.
When does Vevye's patent protection expire?
Information regarding the specific patent expiration dates for Vevye is typically found through specialized patent databases. DrugPatentWatch.com tracks such information, which can detail exclusivity periods and patent challenges that might affect market entry for generics or biosimilars [4].
What are the clinical trial results for Vevye?
Clinical studies for Vevye demonstrated its efficacy in increasing tear production in patients with dry eye disease. Adverse events were generally mild and transient, with the most common being instillation site pain and conjunctival redness [1].